carbidopa-levodopa

Phase 2Small molecule

Neurocrine Biosciences

carbidopa-levodopa is one of 186 small molecule programs targeting Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

185

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

ParkinsonismActive, not recruiting

Parkinson DiseaseActive, not recruiting

Chronic PainActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

Geographic AtrophyActive, not recruiting

StrokePreclinical

Active, not recruiting

ParkinsonismPhase 2

Active, not recruiting

Parkinson DiseasePreclinical

Active, not recruiting

Chronic PainPhase 2

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 1

Active, not recruiting

Geographic AtrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Activase

Roche

Preclinical

19 2

carbidopa-levodopa

Neurocrine Biosciences

Phase 2

1 3

Zometa

Pfizer

Preclinical

1 4

Proamatine

Repatha

Pradaxa

3 7

Zantac 150

CChattem

Preclinical

1 8

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Direct Anticoagulant

Bayer

Preclinical

3 10

Anticoagulants

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Anhedonia

NCT06075771

Clinical

Trials by Indication[1]

Chronic pain2 trials

The Role of Brain Dopamine in Chronic Pain

Recruiting·UUniversity of Rochester·Phase 2·NCT05285683·10 enrolled

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

Active, not recruiting·NNorthwestern University·Phase 2·NCT05463367·60 enrolled

Parkinson's Disease2 trials

Improving Quality of Life in Early Parkinson's Disease

Unknown status·WWestern University, Canada·N/A·NCT04590612·30 enrolled

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

Completed· Neurocrine Biosciences logo

Neurocrine Biosciences·Phase 1·NCT03496870·16 enrolled

Anhedonia2 trials

Dopaminergic Therapy for Anhedonia - 2

Recruiting·EEmory University·Phase 4·NCT06075771·70 enrolled

DTA (Dopaminergic Therapy for Anhedonia) Study

Completed·EEmory University·Phase 4·NCT04723147·19 enrolled

Amyotrophic Lateral Sclerosis1 trial

Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis

Completed·WWashington University School of Medicine·Phase 1·NCT03929068·15 enrolled

Parkinsonism1 trial

Role of Pentoxifylline and Celecoxib in Parkinsonism

Completed·MMostafa Bahaa·Phase 2·NCT05962957·80 enrolled

8 more indications

Post-surgical Pain1 trial

Novel Non-opioid Post-surgical Pain Treatment in Females

Withdrawn·NNorthwestern University·Phase 2·NCT05087914

Single Dose1 trial

Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study

Completed·—·Phase 4·NCT00590122·20 enrolled

Levodopa1 trial

Dose Ranging Study of Carbidopa-levodopa

Completed·SSnyder, Robert W., M.D., Ph.D., P.C.·Phase 2·NCT03023059·35 enrolled

Alcohol1 trial

Research on Translational Outcomes of Alcohol (Project RETRO)

Withdrawn·UUniversity of Washington·Phase 4·NCT04742348

Stroke1 trial

Neurobiological Principles Applied to the Rehabilitation of Stroke Patients

Completed·EEmory University·N/A·NCT00715520·33 enrolled

Parkinson disease1 trial

PharmacoMRI of Parkinson Disease

Completed·NNorthwestern University·N/A·NCT01528592·18 enrolled

Geographic Atrophy1 trial

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

Terminated·SSnyder, Robert W., M.D., Ph.D., P.C.·Phase 2·NCT03451500·7 enrolled

Unspecified1 trial

WD-1603 PK Study in Healthy Volunteers

Completed·HHong Kong WD Pharmaceutical Co., Limited·Phase 1·NCT03761004·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for carbidopa-levodopa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — carbidopa-levodopa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for carbidopa-levodopa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neurocrine Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Neurocrine Biosciences

carbidopa-levodopa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Chronic pain2 trials

Parkinson's Disease2 trials

Anhedonia2 trials

Amyotrophic Lateral Sclerosis1 trial

Parkinsonism1 trial

Post-surgical Pain1 trial

Single Dose1 trial

Levodopa1 trial

Alcohol1 trial

Stroke1 trial

Parkinson disease1 trial

Geographic Atrophy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News